Details
Category: Volume 09 Issue 04 April 2021
Hits: 2007

Title: Efficacy and Safety of Mifepristone vs Ulipristal Acetate in Medical Management of Fibroid- A Comparative Study

Authors: Prof. (Dr) Saroj Singh, Dr Anu Pathak, Dr Divya Yadav, Dr Pearl Jain

 DOI: https://dx.doi.org/10.18535/jmscr/v9i4.09

Abstract

Background: Uterine fibroids are a non-cancerous benign tumor that originates from the smooth muscle layer and the accompanying connective tissue of uterus. A majority of women suffering from fibroids remain largely asymptomatic. Medical management of fibroids aims at providing an alternative to those patients who earlier had only surgical options.

Mifepristone and Ulipristal Acetate are Selective Progesterone Receptor Modulator that reduce the size of the fibroid and uterine volume and hence have the potential to provide relief from symptoms.

Aim: This study was performed to compare the efficacy and safety of Mifepristone vs. Ulipristal acetate for the treatment of symptomatic uterine fibroids.

Method: This study was conducted in the outpatient department of obstetrics and Gynecology, S. N. medical college, Agra. 100 female patients fulfilling the inclusion and exclusion criteria were selected for the study.

Conclusion: We conclude from the study that both the drugs can be used effectively for the treatment of uterine fibroids but Mifepristone proved to be better in reducing fibroid size.

Keyword: Fibroid, Mifepristone, Ulipristal Acetate.

References

  1. Maruo T, Matsuo H, Samoto T, et al. Effects of progesterone on uterine leiomyoma growth and apoptosis. Steroids 2000; 65(10–11): 585–592.
  2. Horak P, Mara M, Dundr P, et al. Effect of a selective progesterone receptor modulator on induction of apoptosis in uterine fibroids in vivo. Int J Endocrinol 2012; 2012: 436174.
  3. Biglia N, Carinelli S, Maiorana A, et al. Ulipristal acetate: a novel pharmacological approach for the treatment of uterine fibroids. Drug Des Devel Ther 2014; 8: 285–292.
  4. Spitz IM. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr Opin Obstet Gynecol. 2009;21:318–24
  5. Narvekar N, Critchley HO, Cheng L, Baird DT. Mifepristone-induced amenorrhoea is associated with an increase in microvessel density and glucocorticoid receptor and a decrease in stromal vascular endothelial growth factor. Hum Reprod. 2006;21: 2312–8. 
  6. Joshi A, Kale S, Chandel S, Pal DK. Likert scale: Explored and explained. Current Journal of Applied Science and Technology. 2015 Feb 20:396-403.
  7. Reid PC, Coker A, Coltart R. Assessment of menstrual blood loss using a pictorial chart: a validation study. BJOG: An International Journal of Obstetrics & Gynaecology. 2000 Mar;107(3):320-2.
  8. Prasad S, Sethi S. Study to compare the efficacy and safety of ulipristal acetate and mifepristone as medical treatment of uterine fibroid. International Journal of Medical and Biomedical Studies. 2019 Sep 28;3(9).
  9. Jayashree V, Mallika A, Roopa K. Mifepristone for medical management of leiomyomata uteri: A prospective study.
  10. Donnez J, Vazquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril 2014; 101(6): 1565–1573.e18.
  11. Ekanem E, Talaulikar V. Medical Therapy for Fibroids: What Next for Ulipristal Acetate?. Advances in Therapy. 2020 Nov 17:1-2.

Corresponding Author

Dr Pearl Jain